Диссертация (1139917), страница 16
Текст из файла (страница 16)
Kato A Et al. Anticancer Res – 2005– № 25 – P. 3741–5.103.Gregory A.E. Vaccine delivery using nanoparticles. / A.E. Gregory, R.Titball, D. Williamson. // Front. Cell. Infect. Microbiol. – 2013 – № 3 – Art 13.131104.Gross PHRM. Stereochemically pure derivatives of muramic andisomuramic Acids / PHRM. Gross // Liebigs. Ann. Chem. – 1986 – P. 37–45.105.Gutierrez O. Induction of Nod2 in myelomonocytic and intestinalepithelial cells via nuclear factor-kappa B activation / O.
Gutierrez, C. Pipaon, N.Inohara, A. Fontalba, Y. Ogura, F. Prosper F, G. Nunez, JL. Fernandez-Luna // J.Biol. Chem. – 2002. – № 277(44) – P. 41701–5.106.Han K.P. IL-15 receptor alpha superagonist complex: high-levelcoexpressionin recombinant mammalian cells, purification and characterization / X.Zhu, B. Liu, E. Jeng, L.
Kong, J.L. Yovandich J.L. et al // Cytokine. – 2011– №56(3)– P. 804–10.107.Hasegawa ASE. Synthesis and immunoadjuvant activity of N-[2-O- (2-acetamido-2,3,di-deoxy-6-thio-D-glucopyranose-3-yl)-D-lactoyl]-L-alanyl-Disoglutamine derivatives. / ASE. Hasegawa, Y. Hioki, M. Kiso, I. Azuma //Carbohydr Res – 1984. – № 129 – P. 271–77.108.Hasegawa ASE. Studies on immunoadjuvant active compounds. PartXXX. Synthesis and immunoadjuvant activity of N-[2-O-(1,5-anhydro-2,3-dideoxy2- octadecanoylamino-D-lactoyl]-L-alanyl-D-isoglutamine and its derivatives /ASE.Hasegawa, K. Kigawa,M.
Kiso, I. Azuma //Agric. Biol. Chem. –1986 – № 50–P. 2133–35.109.Hasegawa AHY. Synthesis and biological activities of N-acetyl-1-thiomuramoyl-L-alanyl-D-isoglutamine and some of its lipophilic derivatives /AHY. Hasegawa, M. Kiso, H. Okumura, I. Azuma // Carbohydr Res.
–1983. – №123 – P. 183–99.110.Hasegawa AOH. Studies on immunoadjuvant active compounds. PartXIV. The chemical modification of the C-2 substituent in the sugar moiety of Nacetylmuramoyl-L-alanyl-D-isoglutamine, and the immunoadjuvamt activities /AOH. Hasegawa, K. Nishibori, Y. Kaneda, M. Kiso, I. Azuma // Carbohydr Res. –1981. – № 97(2) – P. 337–45.111.Hasegawa AKY. Studies on immunoadjuvant active compounds. PartII. A facile synthesis of N-acetylmuramyl-L-alanyl-D-isoglutamine and its132carbohydrate analogs, and their immunoadjuvant activities / AKY.
Hasegawa, M.Amano, M. Kiso, I. Azuma // Agric Biol Chem. – 1978. – № 42 – P. 2187–89.112.Hemmi KTH. Total synthesis of FK-156 isolated from a Streptomycesas an immnostimulating peptide: application of a novel copper chelate aminoprotection / KTH. Hemmi, S. Okada, O. Nakaguchi, Y. Kitamura, M. Hashimoto //J. Am. Chem Soc. – 1981. – № 103– P. 7026–28.113.Heinzelmann, M. Endotoxin and muramyl dipeptide modulate surfacereceptor expression on human mononuclear cells / M. Heinzelmann, HC. Polk, A.Chernobelsky J, TP. Stites, LE. Gordon. // Immunopharmacology. – 2000. – №48(2).
– Р. 117–28.114.Hirota S.A. The NLRP3 inflammasome plays key role in the regulationof intestinal homeostasis / S.A. Hirota, J. Ng, A. Lueng. // Inflamm. Bowel. Dis. –2011 – № 17 (6) – P. 1359–1372.115.Hugot JP. Association of NOD2 leucine-rich repeat variants withsusceptibility to Crohn’s disease / JP. Hugot, M. Chamaillard, H.
Zouali, S. Lesage,JP. Cezard, J. Belaiche, S. Almer, C. Tysk, CA. O’Morain, M. Gassull, V. Binder,Y. Finkel, A. Cortot, R. Modigliani, P. Laurent-Puig, C. Gower-Rousseau, J. Macry,JF. Colombel, M. Sahbatou, G. Thomas // Nature. – 2001. – № 411(6837) – P. 599–603.116.Inohara N. Nod1, an Apaf-1-like activator of caspase-9 and nuclearfactor-kappa B / N. Inohara, T.
Koseki, L. del Peso, Y. Hu, C. Yee, S. Chen, R.Carrio, J. Merino, D. Liu, J. Ni, G. Nunez // J. Biol. Chem. – 1999. – № 274(21) –P. 14560–7.117.Inohara N. Host recognition of bacterial muramyl dipeptide mediatedthrough NOD2 Implications for Crohn’s disease / N. Inohara, Y. Ogura, A. Fontalba,O. Gutierrez, F. Pons, J. Crespo, K. Fukase, S. Inamura, S. Kusumoto, M.Hashimoto, SJ. Foster, AP. Moran, JL. Fernandez-Luna, G. Nunez // J Biol Chem.– 2003.
– № 278(8). – P. 5509–12.133118.Inohara N. The NOD: a signaling module that regulates apoptosis andhost defense against pathogens / N. Inohara, G. Nunez // Oncogene. – 2001. – №20(44) – P. 6473–81.119.Inohara N. NODs: intracellular proteins involved in inflammation andapoptosis / N.
Inohara, G. Nunez // Nat. Rev. Immunol. – 2003. – № 3(5) – P. 371–82.120.Izumi SNK. Antitumor effects of novel immunoactive peptides, FK-156 and its synthetic derivatives / SNK. Izumi, T. Gotoh, S. Hashimoto, T. Kino, M.Okuhara // J. Antibiotics. – 1983. – № 36 – P. 566–74.121.Jeong Y-J. Nod2 and Rip2 contribute to innate immune responses inmouse neutrophils / Y.-J Jeong, M-J. Kang, S-J. Lee et al. // Immunology. – 2 014 –№ 143(2) – P.
269-276.122.Jiang J., Cytokine-induced killer cells promote antitumorimmunity / C.Wu, B. Lu // J. Transl. Med. – 2013 – № 11– P. 83.123.Jorgensen, PF. Peptidoglycan and lipoteichoic acid modify monocytephenotype in human whole blood / PF. Jorgensen, JE. Wang, M. Almlof, C.Thiemermann, SJ. Foster, R. Solberg, AO. Aasen // Clin Diagn Lab Immunol. –2001. – № 8(3). – Р. 515–21.124.Kalyuzhin O.V. Distinctive immunomodulating properties andinteractivity with model membranes and cells of two homologous muramyldipeptide derivatives / O.V.
Kalyuzhin, A.E. Zemlyakov, B.B. Fuchs // Int. J.Immunopharmacol. – 1996. – Vol. 18. – №. 11. – P. 651-659.125.Kamisango KSI. Chemical synthesis and adjuvant activity of N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP) analogs / KSI Kamisango, Y.Tanio, S. Kobayashi, T.
Fukuda, I. Sekikawa, I. Azuma, Y. Yamamura // ChemPharm Bull. – 1981. – № 29 – P. 1644–54.126.Kamphuis T. Immunogenicity and protective capacity of a virosomalrespiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice/ T. Kamphuis, T. Meijerhof, T. Stegmannet al.// I. PLoS. One. –2012. – № 7 (5) –Art e36812.134127.Kang S.J. Antimicrobial peptides: their physicochemical properties andtherapeutic application / S.J. Kang, D.H. Kim., T. Mishig-Ochir, B.J. Lee. // ArchPharm Res – 2012. – №35 (3) – P. 409–413.128.Kelsall, B. Getting to the guts of NOD2 / B. Kelsall.
//Nat. Med. – 2005.– № 11(4) – P. 383–4.129.Killion, JJ. Therapy of cancer metastasis by tumoricidal activation oftissue macrophages using liposome-encapsulated immunomodulators / JJ. Killion,IJ. Fidler // Pharmacol Ther. – 1998. – № 78(3). – Р. 141–54.130.KikeljD.N-[trans-2-[[2′-(acetylamino)cyclohexyl]oxy]acetyl]-L-alanyl-D-glutamic acid: a novel immunologically active carbocyclic muramyldipeptide analogue / D. Kikelj, S.
Pecar, V. Kotnik, A. Stalc, B. Wraber-Herzog, S.Simcic, A. Ihan, L. Klamfer, L. Povsic, R. Grahek, E. Suhadolc, M. Hocevar, H.Honig, R. Rogi-Kohlenprath // J. Med. Chem. – 1998. – № 41(4) – P. 530-9.131.Kobayashi K. IRAK-M is a negative regulator of Toll-like receptorsignaling / K.
Kobayashi, LD. Hernandez, JE. Galan, CA. Janeway Jr, R. Medzhitov,RA. Flavell // Cell. – 2002. – №110(2) – P. 191–202.132.Kobayashi, KS. Nod2- dependent regulation of innate and adaptiveimmunity in the intestinal tract / KS. Kobayashi, M. Chamaillard, Y. Ogura, O.Henegariu, N. Inohara, G. Nunez, RA. Flavell // Science. – 2005. – № 307(5710).
–P. 731–4.133.Kobayashi K. RICK /Rip2 /CARDIAK mediates signalling forreceptors of the innate and adaptive immune systems / K. Kobayashi, N. Inohara,LD. Hernandez, JE. Galan, G. Nunez, CA. Janeway, R. Medzhitov, RA. Flavell //Nature. – 2002. – № 416(6877) – P. 194–9.134.Kobayashi SFT.
Synthesis of muramyl dipeptide analogs withenchanced adjuvant activity / SFT. Kobayashi, H. Yukimasa, M. Fujino, I. Azuma,Y. Yamamura // Bull Chem Soc Jpn. – 1980. – №53 – P. 2570–77.135.Kobayashi SFT. Synthesis, and the adjuvant and tumor-suppressiveactivities of quinonyl muramyl dipeptides /SFT.
Kobayashi, F. Yukimasa, M.135Fujino, I. Azuma, Y. Yamamura // Bull Chem Soc Jpn. – 1984. – №57 – P. 3182–96.136.Kochenderfer J.N. Eradication of B-lineage cells and regression oflymphoma in a patient treated with autologous T cells genetically engineered torecognize CD19.
W.H. Wilson, J.E. Janik, M.E. Dudley, M. Stetler-Stevenson, S.A.Feldman et al. // Blood. –2010 –№ 116(20) – P. 4099–102.137.Kotani S. Immunoadjuvant activities of synthetic N-acetyl-muramyl-peptides or -amino acids / S. Kotani, Y. Watanabe, F. Kinoshita, T. Shimono, I.Morisaki // Biken J. – 1975. – № 18(2). – Р. 105–11.138.Kufer TA. Role for erbin in bacterial activation of Nod2 / TA. Kufer,E. Kremmer, DJ. Banks, DJ. Philpott // Infect.
Immun. – 2006 – № 74(6) – P. 3115–24139.Kubasch NSRR. Synthesis of muramyl peptides containing meso-diaminopimelic acid Eur / NSRR. Kubasch //J. Org. Chem. – 2002. – P. 2710–26.140.Kusumoto SIM. Synthesis of long chain fatty acid esters of N-acetylmuramyl-L-alanyl-D-isoglutamine in relation to antitumor activity / SIM.Kusumoto, T Shiba // Tetrahedron Lett. – 1978. – № 49 – P. 4899–902.141.Lala S. Crohn’s disease and the NOD2 gene: a role for paneth cells / S.Lala, Y.
Ogura, C. Osborne, SY. Hor, A. Bromfield, S. Davies, O. Ogunbiyi, G.Nunez, S. Keshav // Gastroenterology. – 2003. – № 125(1) – P. 47–57.142.LanghansW.Differentialfeedingresponsestobacteriallipopolysaccharide and muramyl dipeptide Am / W. Langhans, G. Balkowski, D.Savoldelli //J Physiol. –1991. – № 261(3 Pt 2). – Р. 659–64.143.Lecine, P. The NOD2-RICK complex signals from the plasmamembrane / P. Lecine, S. Esmiol, JY. Metais, C.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
